Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Patient characteristics of the three classes stratified by rheumatoid factor and anti-cyclic citrullinated peptide antibodies

From: High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study

  Low/low class (n = 53) Middle class (n = 183) High/high class (n = 71) p Value
RF, IU/ml 11 (5, 30) 87 (50, 139) 384 (248, 604) < 0.0001
Anti-CCP, U/ml 7 (2, 22) ≥ 100 (38, ≥ 100) ≥ 100 (≥ 100, ≥ 100) < 0.0001
Female sex 89% 83% 76% 0.1766a
Age, years 46.4 (13.0) 49.3 (12.1) 53.0 (10.3) 0.0093
BMI 22.2 (4.2) 22.0 (3.3) 22.8 (3.9) 0.3774
Disease duration 7.3 (6.9) 7.9 (7.2) 8.6 (8.7) 0.8541
NSAID use 89% 87% 90% 0.8299a
Glucocorticoid use 66% 70% 65% 0.6263a
DMARD (other than MTX) use 32% 31% 31% 0.9793a
MTX dose, mg/week 7.6 (1.7) 7.9 (1.8) 7.7 (1.7) 0.5264
Duration of MTX use 2.7 (2.6) 2.7 (2.8) 2.6 (2.8) 0.9885
Comorbidity 77% 74% 87% 0.0810a
DAS28-CRP 5.54 (4.92, 6.42) 5.39 (4.89, 6.01) 5.74 (5.12, 6.37) 0.0251
Total modified Sharp score 36.0 (8.0, 56.8) 36.5 (12.0, 74.1) 31.5 (13.0, 57.0) 0.4305
HAQ 1.21 (0.68) 1.11 (0.63) 1.38 (0.67) 0.0132
MMP-3, ng/ml 262 (132, 561) 207 (105, 420) 196 (101, 352) 0.2372
IL-6, pg/ml 26.5 (12.3, 56.5) 28.5 (12.4, 70.2) 33.6 (15.1, 61.8) 0.6163
TNF, pg/ml 0.73 (< 0.55, 1.09) 0.91 (< 0.55, 1.23) 1.15 (0.72, 1.82) 0.0002
 Low/intermediate/highb 38%/55%/8% 29%/63%/8% 20%/51%/30% 0.0007
  1. Abbreviations: BMI Body mass index, CCP Cyclic citrullinated peptide antibodies, DAS28-CRP Disease Activity Score in 28 joints based on C-reactive protein, HAQ Health Assessment Questionnaire, IL-6 Interleukin-6, MMP-3 Matrix metalloproteinase-3, MTX Methotrexate, NSAID Nonsteroidal anti-inflammatory drug, RF Rheumatoid factor, Rho Spearman’s rank correlation coefficient, TNF Tumor necrosis factor
  2. Data are mean (SD), median (interquartile range), or patients rate (%). The Kruskal-Wallis test was used to evaluate the differences among three classes unless otherwise noted
  3. aChi-square test was used to evaluate the differences among three classes
  4. bDistribution of TNF levels were defined as follows: low < 0.55, intermediate ≥ 0.55 to < 1.65, and high ≥ 1.65 pg/ml [18]